University of Kentucky

UKnowledge
Pharmaceutical Sciences Faculty Publications

Pharmaceutical Sciences

7-2013

Metal-Based Nanoparticle Interactions with the Nervous System:
The Challenge of Brain Entry and the Risk of Retention in the
Organism
Robert A. Yokel
University of Kentucky, ryokel@email.uky.edu

Eric A. Grulke
University of Kentucky, eric.grulke@uky.edu

Robert C. Macphail
U.S. Environmental Protection Agency

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/ps_facpub
Part of the Chemical Engineering Commons, Medical Toxicology Commons, and the Pharmacy and
Pharmaceutical Sciences Commons

Metal-Based Nanoparticle Interactions with the Nervous System: The Challenge
of Brain Entry and the Risk of Retention in the Organism
Digital Object Identifier (DOI)
https://doi.org/10.1002/wnan.1202

Notes/Citation Information
Published in Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, v. 5, issue 4.
Copyright © 2013 Wiley Periodicals, Inc.
The copyright holder has granted the permission for posting the article here.
This is the peer reviewed version of the following article:
Yokel, R., Grulke, E., & MacPhail, R. (2013). Metal-based nanoparticle interactions with the nervous
system: The challenge of brain entry and the risk of retention in the organism. Wiley Interdisciplinary
Reviews: Nanomedicine and Nanobiotechnology, 5(4), 346-373, which has been published in final form at
https://doi.org/10.1002/wnan.1202
This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions
for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed
into a derivative work, without express permission from Wiley or by statutory rights under applicable
legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to
Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making
available the article or pages thereof by third parties from platforms, services and websites other than
Wiley Online Library must be prohibited.

This review is available at UKnowledge: https://uknowledge.uky.edu/ps_facpub/181

Metal-based nanoparticle interactions with the nervous system: the challenge of brain
entry and the risk of retention in the organism
Yokel, Robert; University of Kentucky,
Grulke, Eric; University of Kentucky, Chemical & Materials Engineering
MacPhail, Robert; U.S. EPA, Neurotoxicology Division
I.SCOPE OF THE REVIEW
II. THE NERVOUS SYSTEM: A PROTECTED ORGAN
III. COLLOIDAL CHEMISTRY INFLUENCES “WHAT THE CELL SEES”
III.A. Colloidal (and nanoparticle) dispersion stability
III.B. Electrostatic stabilization
III.C. Stabilization systems
III.C.1. Surfactants and micelles
III.C.2. Coupling agents
III.C.3. Polymers for steric protection
IV. ENVIRONMENTAL FACTORS THAT INFLUENCE “WHAT THE CELL SEES”
IV.A. Milieu pH
IV.B. Solubility
V. METAL-BASED NANOPARTICLES AND THE NERVOUS SYSTEM: SCOPE OF
THE KNOWLEDGE
VI. ROUTES OF AND BARRIERS TO BRAIN NANOPARTICLE UPTAKE
VI.A. Nanoparticle uptake through the blood-brain barrier
VI.B. Sites lacking an intact blood-brain barrier
VI.C. Nanoparticle uptake through the choroid plexuses
VI.D. Direct uptake into the brain through cranial nerves exposed to the
environment
VI. E. Direct introduction of nanoparticles into the brain
VII. THE PHARMACOKINETICS OF BRAIN NANOPARTICLE UPTAKE AND
DISTRIBUTION
VII.A Nanoparticle factors that influence central nervous system (CNS) uptake
VII.A.1. Size
VII.A.2. Shape
VII.A.3. Surface charge (in relation to luminal surface of brain endothelial cells)
VII.A.4. Surface coating (intended and opsonization)
VII.B. Subcellular nanoparticle localization
VIII. THE PHARMACODYNAMICS OF NANOPARTICLES IN THE NERVOUS
SYSTEM
VIII.A. Blood-brain-barrier responses to nanoparticles
VIII.B. Animal responses to nanoparticles
VIII.C. Nervous system responses to nanoparticles not seen in the nervous
system
VIII.D. Physical-chemical factors that affect biological responses
VIII.D.1. Size
VIII.D.2. Shape
VIII.D.3. Surface charge
VIII.D.4. Surface coating
1

IX. NANOPARTICLE NERVOUS SYSTEM INTERACTIONS OUTSIDE OF THE BRAIN
IX.A. The blood-peripheral nerve barrier to nanoparticle uptake into the peripheral
nervous system (PNS)
IX.B. Nanoparticle effects on the spinal cord and peripheral nervous system
X. IN VITRO STUDIES WITH BRAIN-DERIVED CELLS
XI. VALIDATION THAT IN VITRO APPROACHES PREDICT IN VIVO EFFECTS
XII.NANOPARTICLE INTERACTION WITH INFRA-MAMMALIAN ANIMAL SPECIES
(ZEBRAFISH, C. ELEGANS, AND DROSOPHILA)
Sidebar 1: Pharmacokinetics of gold nanoparticle nervous system entry, influencing
factors, and extent of entry
Sidebar 2: Gold nanoparticle nervous system pharmacodynamics
XIII. CONCLUSIONS AND RESEARCH NEEDS
XIV. REFERENCES
ABBREVIATIONS:
BBB
blood-brain barrier
BCSFB
blood cerebrospinal fluid barrier
BMEC
brain microvascular endothelial cells
BNB
blood-nerve barrier
BRB
blood-retinal barrier
CSF
cerebrospinal fluid
CT
computed tomography
CNS
central nervous system
DRG
dorsal root ganglia
GFAP
glial fibrillary acidic protein
LOEL
lowest observable effect level
MRI
magnetic resonance imaging
NOEL
no observable (observed) effect level
NP
nanoparticle
NS
nervous system
PAMAM
poly(amido amine)
PEG
polyethylene glycol
PNS
peripheral nervous system
QD
quantum dot
ROS
reactive oxygen species
SPION
superparamagnetic iron oxide NP
TEM
transmission electron microscopy
ζ potential zeta-potential

2

Abstract
This review of metal- and metal-oxide-based nanoparticles focuses on factors that
influence their distribution into the nervous system, evidence that they enter brain
parenchyma, and nervous system responses. Emphasis is placed on gold as a model
metal-based nanoparticle and for risk assessment in the companion review. The
anatomy and physiology of the nervous system, basics of colloid chemistry, and
environmental factors that influence what cells see are reviewed to provide background
on the biological, physical-chemical, and internal milieu factors that influence nervous
system nanoparticle uptake. The results of literature searches reveal little nanoparticle
research has included the nervous system, which about equally involved in vitro and in
vivo methods, and very few human studies. The routes of uptake into the nervous
system and mechanisms of nanoparticle uptake by cells are presented with examples.
Brain nanoparticle uptake inversely correlates with size. The influence of shape has not
been reported. Surface charge has not been clearly shown to affect flux across the
blood-brain barrier. There is very little evidence for distribution of metal-based
nanoparticles into brain parenchyma. Metal-based nanoparticle disruption of the bloodbrain barrier and adverse brain changes have been shown, and are more pronounced
for spheres than rods. Study concentrations need to be put in exposure contexts. Work
with dorsal root ganglion cells and brain cells in vitro show the potential for metal-based
nanoparticles to produce toxicity. Interpretation of these results must consider the ability
of nanoparticles to distribute across the barriers protecting the nervous system of the
intact organism. Effects of the persistence of poorly soluble metal-based nanoparticles
are of particular concern.
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I. SCOPE OF THE REVIEW
Much has been reported on polymer-based drug delivery systems that target the brain.
A prior review in this forum focused on carbon-based and quantum dot (QD)
nanoparticles (NPs) 1. This review of the English language literature of metal and metaloxide based NPs (≤ 100 nm) focuses on the factors that influence their distribution into
the brain, evidence that they enter brain parenchyma, and their biological responses.
NPs are being investigated as delivery systems to the brain, including MRI contrast
agents, photosensitizers for diagnosis, labeling, tumor site identification, and as
therapeutic agents, especially to treat cancer. Industrial applications include: fuel cells,
batteries, nanocomposites, coatings, and catalysts. This review has relevance for risk
assessment of metal-based NPs with the central nervous system (CNS).
Risk assessment requires information on NP characterization, fate, accumulation,
translocation, release, and effects. A critical issue for risk assessment is whether
current in vitro and in vivo results are based on solid knowledge of the dose
characteristics and mechanisms for adsorption, distribution, metabolism, and elimination
2. The present review provides some background for these conundrums, emphasizing
gold as a model NP. Data for gold NPs are used as a model for risk assessment in the
companion review 2. Core NP physical-chemical characterization properties include
chemical composition and impurities, crystallinity, shape, and morphology/chemistry of
surface functional groups (intentional coatings and/or agents that become associated
with the NP surface, including proteins, surfactants and environmental colloids such as
humic acids). The roadmap of this review is the nervous system (NS) as a protected
organ, the colloidal chemistry of NPs, and the pharmacokinetic and pharmacodynamic
interactions of NPs with the NS.
II. THE NERVOUS SYSTEM: A PROTECTED ORGAN
There is concern that NPs may compromise the NS which has properties that render it
uniquely susceptible to insult. The NS is divided into the central NS (CNS) comprised of
the brain and spinal cord, and peripheral NS (PNS), comprised of 12 pairs of cranial and
31 pairs of spinal nerves that connect the CNS to organs, muscles and glands.
Outgoing (effector) neurons mediate motor activity and autonomic activity. Incoming
(sensory) neurons provide visual, hearing, smell/taste, proprioception (body position),
and pain/itch information. The afferent neurons pass through the spinal nerve dorsal
root ganglia (DRG), comprised of neuronal cell bodies that lie along the back of the
vertebral column (spine). The CNS has many sites of specialized function.
The CNS is enclosed in 3 meninges (the dura, arachnoid and pia membranes).
Cerebrospinal fluid (CSF) fills a compartment comprised of 4 ventricles within the brain,
a canal within the spinal cord, and the sub-arachnoid space between the arachnoid and
pia membranes that surrounds the brain and spinal cord,. This fluid-filled compartment
dampens mechanical shock to the CNS. Most CSF is produced by choroid plexuses in
the brain’s 4 ventricles. Some comes from brain extracellular (interstitial) fluid, that
comprises 20% of the brain volume, flowing along capillary and artery walls, into the
brain’s ventricles. Drainage of fluid and substances from the human brain is primarily via
CSF, giving the opportunity to indirectly monitor the brain’s biochemical activity. Most
CSF drains into blood through the arachnoid villi, although a small percentage drains
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into the lymphatic system 3. Lymphatic system drainage accounts for a greater
percentage of fluid drainage from the brain in rats, rabbits and sheep. Lymphatic
drainage from rat brain into cervical lymph nodes was demonstrated with a dextrancoated 20 to 200 nm superparamagnetic iron oxide NP (SPION) and MRI 4.
There are 2 cell types in the normal brain, neurons and glial cells. Although generally
thought that there are 10-fold more glial cells than the ~100 billion neurons in the human
brain, the ratio may not be this great, and may be close to 1 5-8. Glia include the
macroglia (neuroglial cells, of neural origin) which are astrocytes and oligodendrocytes,
and the microglia. Neurons are thought to be post-mitotic in most mammalian brain
regions. They are particularly sensitive to insult because of their high metabolic
requirements and long processes (axons up to a meter long, and dendrites) with large
surface areas that depend on the cell body for protein synthesis and much metabolism.
The human brain is 2% of the typical body mass but receives 15% of the blood, utilizes
20% of the body’s resting oxygen and energy consumption, and is fueled largely by
transporter influx of glucose. The macroglia have a negative resting membrane
potential, but do not propagate action potentials. They are physically connected by gap
junctions to from a functional network. Glial cells express voltage-gated ion channels
similar to those seen in neurons, are able to express receptors to many of the same
neurotransmitters and neuromodulators as neurons, have transporters to take up many
neurotransmitters, and can release some neurotransmitters. Astrocytes play a role in
regulation of neuro- and gliogenesis, neuronal path finding and regulation of
synaptogenesis; form the scaffold of the NS; contribute to and regulate the BBB;
regulate cerebral microcirculation; provide energy substrates for neurons; and provide a
favorable extracellular milieu by regulating extracellular potassium and pH and taking up
neurotransmitters. The oligodendrocytes in the CNS have 4 to 6 processes that produce
myelin which insulates axons between nodes of Ranvier, assisting fast saltatory action
potential propagation. Schwann cells in the PNS myelinate axons and also perform
some functions that astrocytes perform. Microglia, of monocyte/macrophage lineage,
are resident immune cells, entering the brain during embryogenesis. In the normal brain
they are in the resting state. They have numerous receptors and immune molecule
recognition sites. The glial response to insults is reactive gliosis. It is manifest as
astrocyte hypertrophy and proliferation, causing increased synthesis of its cytoskeletal
intermediate filament glial fibrillary acidic protein (GFAP) and axonal degeneration
(Wallerian degeneration), due to loss of myelination. In response to many stressors,
including injury, inflammation, infection, lipopolysaccharide, foreign matter, and brain
implants, as well as reduction of normal brain activity, microglia can be activated to a
reactive state within hours, upregulating potassium channels, down-regulating neuronal
and upregulating immunocompetent receptors, increasing enzyme synthesis, and
increasing surveillance of brain activity. Some proceed to become phagocytic microglia.
Microglial over-activation can contribute to neuronal damage and neurodegenerative
disorders 5. For more background on brain cells see 5, 9.
III. COLLOIDAL CHEMISTRY INFLUENCES “WHAT THE CELL SEES”
As noted by 10, “Nanoparticles in solution are called colloids.” A review of colloid
chemistry provides insight into NP physical-chemical properties that impact their uptake,
distribution, pharmacodynamics, dosimetrics, and biological fate 11-14. In a colloidal
5

system one substance is microscopically dispersed throughout another. The dispersed
phase particles are usually 1 to 1000 nm. The dispersed and continuous phases may be
gas, liquid, or solid (except a gas/gas system which is miscible and would not be
considered a colloid). The stability of colloidal dispersions (that is, whether they remain
as discrete particles or agglomerate, aggregate, or flocculate) depends on whether the
discrete phase surface chemistry renders a thermodynamically stable dispersion in the
continuous phase. 1
III. A. Colloidal (and nanoparticle) dispersion stability
Forces that affect the stability of colloidal systems include: excluded volume repulsion
(hard particles cannot overlap), electrostatic interaction (colloid particles often carry
electric charge and can repel or attract one another), van der Waals forces (permanent
or induced dipoles in particles can repel or attract), entropic forces (systems of particles
will tend to maximize entropy, leading to interparticle forces), and steric interactions
(polymers adsorbed to surfaces can provide physical barriers that prevent close
approach of potentially attractive charges). Mutual repulsion of like electrical charges
on NP colloids leads to electrostatic stabilization. Steric stabilization of colloids occurs
when coatings such as polymers or oligomers are attached to NP surfaces; these
coatings prevent them from approaching close enough that attractive forces would
become effective, thus preventing agglomeration. Many commercial NP products have
surface coatings/functionalizations that are designed to control their dispersion in
specific media. These materials are referred to as complex NPs 15 or nanocomplexes 16,
terms increasingly used in the literature.
III.B. Electrostatic stabilization
Charge stabilization is an important way to control coalescence of colloidal dispersions
11. Colloidal stability is usually defined as the tendency for particles to
agglomerate/aggregate or form sediment. Electrostatic stabilization is based on charged
double layers that develop around colloid particles in polar liquids. The charge on the
surface of the colloid induces opposite charges in the local liquid. The charged region
can extend some distance from the hard particle surface, and can be quite sensitive to
salt concentrations, ion types (multivalent ions in particular), and pH. This is shown in
Figure 1, that illustrates two solid colloidal particles (gray spheres), that have a negative
surface charge, in a dispersion. Positive ions (pink) form a dense layer near the
negatively charged solid surfaces. These ions attract negative ions (blue) via coulombic
forces, forming a second, more diffuse layer. Interfacial double layers are important for
Agglomerate: A collection of weakly bound particles or aggregates or mixtures where the resulting external
surface area is similar to the sum of the surface areas of the individual components
http://www.iso.org/obp/ui/#iso:std:iso:ts:80004:-4:ed-1:v1:en (accessed 8-14-2012).
Aggregate: A particle composed of strongly bonded or fused particles where the resulting external surface area
may be significantly smaller than the sum of calculated surface areas of the individual components
http://www.iso.org/obp/ui/#iso:std:iso:ts:80004:-4:ed-1:v1:en (accessed 8-14-2012).
Flocculant: In chemistry this is a process wherein colloids come out of suspension in the form of floc or flakes by
the addition of a clarifying agent. The action differs from precipitation in that prior to flocculation colloids are
merely suspended in a liquid and not actually dissolved in a solution. In the flocculated system, there is no
formation of a cake, since all the flocs are in the suspension (www.wikipedia.com).
Coalescence: A process in which two phase domains (droplets, bubbles or particles) of the same composition come
together and form a larger phase domain http://en.wikipedia.org/wiki/Coalescence (accessed 8-14-2012).
1
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systems with large ratios of surface area to volume. The total potential energy of
interaction for a pair of colloid particles in solution is linked to attractive (e.g., van der
Waals) and repulsive forces. Attractive forces have been modeled by Hamaker and de
Boer; this potential energy is directly proportional to the particle radius and the Hamaker
constant (describing the interaction between the particle and the continuous phase),
and inversely proportional to the inter-particle separation distance 11.
Electrostatic repulsion forces stabilize particles in aqueous or polar organic media. The
zeta-potential (ζ) of the colloid can be used as a measure of the thickness of the double
layer, as shown in Figure 1. Zeta potential measurements are used to estimate the
double layer charge. The small graph on the right hand side of Figure 1 shows the
change in electrical potential at various distances from the colloid surface. Voltage
gradients (V/m) can be very steep in the vicinity of colloids, which affects their stability in
the dispersion. The ζ potential, which is calculated using theoretical models and
experimentally-determined electrophoretic mobilities, is the electrical potential in the
double layer between the ‘slipping layer’ (denoted by the outer black dashed line) and a
point in the bulk fluid. The total ζ potential is taken to be the linear addition of the
attractive and repulsive forces. This function usually has a maximum, creating an
activation energy for agglomeration. For agglomeration to occur, two particles must
collide with sufficient energy to overcome this barrier. Inside the slipping layer, the local
fluid, including ions, moves with the colloidal particle. In Figure 1, the positive ions
induced toward the negative charges on the colloid surface have a gradient that
decreases rapidly with distance due to the negative ions moving in from the bulk
solution. A system with a high absolute value of the ζ potential, > 40 mV for example,
has high repulsive charges at the point where local fluid moves relatively independently
from the particle. Such a system should be electrically stable, and resistant to
agglomeration, coagulation, or flocculation. Electrostatic stabilization provides kinetic
but not thermodynamic ‘stability’, which always tends toward
agglomeration/aggregation. Stability can be influenced by salt concentration, ion type, ζpotential, and particle size 11. As the salt concentration increases, the double layer
thickness decreases and more collisions will lead to agglomeration. For example, a 30
mM sodium chloride (NaCl) solution has a double layer thickness of 2 nm, while a 0.1
mM NaCl solution has a double layer thickness of 30 nm. When multivalent ions are
present the electrolyte concentration needed for coagulation can decrease by orders of
magnitude. Repulsive energy is proportional to the square of the measured ζ-potential;
these values are often used to tune a dispersion to attain kinetic stability. In general, a
larger particle radius leads to a higher energy barrier.
III.C. Stabilization systems
There are a variety of stabilization systems used for NP dispersions, including
surfactants, coupling agents, and polymers. Each of these stabilization systems can
have specific responses to subtle changes in the NP’s environment, reducing
uncertainty about long-term stability of these dispersions.
III.C.1. Surfactants and micelles
Surfactants, by lowering the surface tension between two phases, can be used to form
micelles by surrounding a material that is insoluble in a medium to enable its
7

introduction into that medium. Surfactants usually protect the growing particle surface.
Surfactants used in water dispersions are usually amphiphilic. They adsorb at
interfaces, such as NP/liquid interfaces. However, surfactants are usually reversibly
adsorbed to NP surfaces, and can desorb as milieu conditions change. Some
surfactants can affect cell processes and are toxic.
III.C.2. Coupling agents
Coupling agents are commonly used to modify NPs for use in a variety of solvents and
polymers. The most common coupling agents are based on silane chemistry. Many
reactive groups and non-reactive ligands are available commercially. As with any
reactive system, it is useful to know the surface density of the reactive group on the
NPs. Covalent bonding to the surfaces of NPs is sensitive to the physical-chemical
properties of their surface and the reaction environment 12.
III.C.3. Polymers for steric protection
Polymer adsorption to NPs depends on polymer charge and molecular weight, and the
aqueous solution conditions (pH, ionic strength and salts). The polymer may have a
variety of conformations on the surface; the electrostatic forces around the complex
particle may be altered, and steric forces may be the major component of the repulsive
forces. Reorientation of the polymer chains near the surface can occur with changes in
environmental conditions. See 13 for a good review.
Polymeric NPs (inverse microemulsions) are being developed for drug delivery
applications, carrying hydrophobic drugs in the micelle interior to specific body sites 14.
For example, coating complex NPs with polyethylene glycol (PEG) surfactants makes
their surface hydrophilic, which can lengthen the time the NP circulates in blood 17.
Particles with sizes less than 100 nm seem to be particularly well-suited for this purpose
(for an example see 18).
IV. ENVIRONMENTAL FACTORS THAT INFLUENCE “WHAT THE CELL SEES”
IV.A. Milieu pH
The milieu pH can influence the NP chemical species, including surface charge and
solubility. It can also affect colloid (NP) stability and fate. For the mammal, some
relevant pHs are in Table 1. The upper gastrointestinal tract and lysosomes are most
likely to affect NP chemical species.
IV.B. Solubility
Solubility can influence the chemical species and effects of NPs. Insoluble ceria-, goldand titania-based NPs have pharmacokinetics, localization, and effects that are different
from their soluble forms 1. This becomes less clear for NPs that are soluble at
physiological pHs, such as copper, iron, silver, and zinc oxide. The following examples
illustrate this. Dissolution of QDs, often composed of a cadmium selenide, cadmium
sulfide, or cadmium selenide tellurium core, releases the toxic metal cadmium 19.
Transmission electron microscopy (TEM) and scanning TEM failed to reveal ~2.2 nm
PEG-coated silver NP in the brain 24 to 168 hours after its intraperitoneal injection,
whereas inductively coupled mass spectrometry (ICP-MS) showed the presence of
silver, presumably due to dissolution and silver ion brain entry 20. All of the toxicity of a
8

zinc oxide NP was thought to be due to solubilized zinc 21. Metal-based NP distribution
is often assessed using destructive elemental analysis techniques, such as “bulk” (e.g.
50 mg) tissue digestion and analysis by ICP-MS; ICP-atomic emission spectroscopy or
ICP-optical emission spectrometry; graphite furnace (electrothermal, flameless) atomic
absorption spectrometry; instrumental neutron activation analysis; or radioactive
analysis. These techniques do not differentiate between intact NP and dissolved metal.
PEG, mercaptoacetic acid, and zinc sulfide coatings have been used to reduce toxicity,
but they do not always prevent dissolution 22.
V. METAL-BASED NANOPARTICLES AND THE NERVOUS SYSTEM: SCOPE OF
THE KNOWLEDGE
Literature searches were conducted to identify numbers of publications and patents
about nanoparticles (a SciFinder® search of the concept “nanoparticle” from 1990
through 2011). The typical search string started with the term, ‘nanoparticles’, and then
was refined by material composition (i.e., gold, carbon black, metals, etc.) or study type
(in vitro or in vivo). The publication count includes all scientific inquiries while the patent
counts point toward commercialization activities. The results are shown in Figures 2 and
3. Nanoparticle, in vitro NP and in vivo NP publications had 32%, 28%, and 30%
exponential growth rates, respectively (Figure 2 A). However, the total NP publications
far exceed those focused on biological systems, reflecting the small percentage of total
effort focused on biological benefits and risks. For example, in 2011, there were 51,806
publications on nanoparticles, with 2960 (6%) linked to in vitro studies and 2575 (5%)
linked to in vivo studies. To understand the extent of reports on NPs and the NS,
SciFinder® searches were conducted using the terms neuron, nerve, glial cell,
astrocyte, oligodendrocyte, and microglia paired with nanomaterial and nanoparticle.
The results were reviewed for studies of metal-based NPs. Two hundred fifty-five
reports were found. This is~0.1% of the NP literature, showing that remarkably few
studies of biological effects of metal-based NPs included NS endpoints. The metal(s)
and research platform(s) (in vitro and/or in vivo) were identified in each report in our
literature searches. Figure 2 (Panel B) shows the predominant metal NPs and research
platforms used (Panel C).
A major use of metal-based NPs is as imaging agents, including SPIONs and QDs.
SPIONS have been investigated for imaging by MRI or combined with a fluorescent or
optical dye in a multimodal nanoplatform for cell labeling, including neural stem cells
that have tropism for glioblastomas, magnetic thermotherapy induced by alternating
magnetic field activation, and external field magnetic targeting. NP surface modification
with agents specific for brain tumors increases tumor targeting 23. Capitalizing on their
intense fluorescent emission, QD-conjugated probes have been used to recognize
glycine, GABAA and tyrosine kinase B receptors, epidermal growth factor receptor,
nerve growth factor, brain tumors, glutamate transporters, cell surface membrane and
fusion proteins, and GFAP; label mammalian CNS neural stem and progenitor cells,
microtubules, GFAP intermediate filament cellular bridges, and aquaporin-4 and P2
receptors; and visualize endocytosis. Some of these have been visualized using single
molecule/particle imaging/tracking. Much of the work so far has been demonstration of
proof of principle. NS-related demonstrations have been mostly conducted in cells in
9

culture, often PC12 cells (derived from a rat adrenal pheochromocytoma; used as a
neuron model).
The clinical applications most often addressed utilized SPIONs for NS visualization by
MRI, cell labeling, and thermotherapy. This has focused on brain cancer 24 and been
suggested for axon regeneration following NS injury 25. Ceria NPs have been suggested
to be a potential anti-oxidant therapeutic agent for neurodegenerative disease 26, but
this has not yet been demonstrated in the intact animal. Studies of metal-based NPs
given to humans to target the NS have been conducted by only a few groups, focusing
on the use of iron oxide as a tumor imaging agent 27, 28 and in magnetic thermotherapy
treatment of glioma 24, 29. To predict the future of NP applications, the number of issued
patents for NPs is shown in Figure 3, as well as those containing metal-based NPs and
selected metals. For example, there were 7182 nanoparticle patents issued in 2011.
Silica- and titania-containing NPs have generally been the focus of more patents than
gold and silver, suggesting more future commercial applications of the former two.
VI. ROUTES OF AND BARRIERS TO BRAIN NANOPARTICLE UPTAKE
The major routes of NP uptake in the human are from the respiratory tract (including the
nasal cavity), gastrointestinal tract, and potentially through the skin. Uptake can lead to
distribution into the central compartment (blood) from which the NP can distribute into
the NS across the blood-brain barrier (BBB), blood-cerebrospinal fluid barrier (BCSFB)
and blood-nerve barrier (BNB). In addition there is a direct route to the brain via cranial
nerves that are exposed to the environment (see: VI.D. Direct uptake into the brain
through cranial nerves exposed to the environment). Absorption of metal-based
NPs from the oral cavity has been demonstrated 30. NP absorption from the colon and
rectum has been described, but not for metal-based NPs. Sublingual NP absorption has
not been well demonstrated. Absorption from the stomach and intestine is related to NP
size 30. Nano titania has been the most studied metal-based NP for dermal uptake due
to its use in sun screen products. In the absence of damage to the skin, organic
solvents and irritant detergents, or skin flexing, there is little evidence of metal-based
NP systemic absorption after dermal application 31.
Hurdles to overcome for NP delivery to the brain from blood include the BBB (discussed
in VI.A. Nanoparticle uptake through the blood-brain barrier) and the clearance of
NPs through distribution, metabolism, and excretion processes that reduce the amount
available to enter the brain. A high percentage of NPs are cleared from circulation by
the mononuclear phagocyte system. Increasing NP delivery to the brain might be
addressed by increasing the NP dose. This presents the risk of increasing undesirable
effects and presenting an even greater NP body burden that creates concern about the
long-term effects of persistent NPs. Another approach is the use of PEG and other
surface modifications to render the NP less recognizable by the mononuclear phagocyte
system. More targeted approaches include surface modification to enhance selective
uptake into the target site, e.g., functionalization recognized only by glioma cells when
treating that condition, the use of magnetic NPs directed to the target brain site by
external field targeting, and short-term opening of the BBB. These approaches are
discussed below.
10

Further hurdles to brain delivery are metabolism and elimination. Metabolism is greatly
influenced by the NP chemical composition, with solubility a significant issue, discussed
in IV.B. Solubility. Another major issue of metabolism is opsonization, discussed in
VII.A.4 Surface coating (intended and opsonization). Molecules < 3 nm are freely filtered
through the kidney’s glomerular capsule; those > 5 nm (~70 kDa) are not. QDs < 5 nm
were renally eliminated 32.
When “bulk” tissue is used to determine NP distribution, and efforts are not made to
remove blood from the animal, the NP in the blood within the tissue contributes to the
bulk tissue NP content. 14C-sucrose very slowly diffuses across the intact BBB and is
used as an indicator of vascular space. Based on 14C-sucrose in the brain immediately
after its i.v. administration, compared to its blood concentration, the vascular volume of
gray matter, white matter, the frontal lobe, cerebellum, and pituitary were calculated to
be 2.7, 1.1, 2.1, 3.5, and 26.8%, respectively 33. Figure 4 shows results of reports where
selected, quite insoluble, metal-based NPs were investigated in “bulk” brain which
reported NP as % of the dose or from which it could be calculated. Many NPs were
either not seen in the brain or poorly entered the brain, which is ~0.5% of rat and 1.75%
of mouse body weight. These results are consistent with a recent statement that “less
than 0.1% of inhaled or systemically injected nanoparticles are found within the brain”
34. With such limited penetration, one might be inclined to discount the CNS as a target
for metal-based NPs, but the literature indicates otherwise.
VI.A. Nanoparticle uptake through the blood-brain barrier
The CNS is insulated from many changes in the body by the BBB and BCSFB; the PNS
by the BNB. These barriers present a formidable challenge to delivery of substances
into the NS and create a pharmacological sanctuary. The anatomical basis of the BBB
includes the brain microvascular endothelial cells (BMECs) that line the ~5 to 10 µm
diameter vessels that perfuse the brain. Their surface area (20 m2) is 10-fold greater
than that of the human body. Unlike the endothelial cells that line capillaries in most
body regions, they are joined by tight junctions that severely limit paracellular flux. Brain
vascular endothelial cells have little bulk (fluid) phase endocytosis or receptor-mediated
endocytosis, and generally lack fenestrations. They have, however, considerable
metabolic activity. They are surrounded by a basement membrane, which is covered by
pericytes on ~30% of its surface. Astrocyte foot processes cover > 95% of this complex.
Rapid flux of substances between blood and brain is possible due to the extensive
distribution of microvessels (which are within ~15 µm of any cell in the brain) 35. Sialic
acid residues on the BBB luminal surface provide a negative charge, which is expected
to influence the ability of charged NPs to approach the BBB 36. Most brain entry,
quantitatively, and the most rapid kinetically, is across the BBB. The mechanism of
metal-based brain NP uptake across the intact BBB is believed to be transcytosis
through the BMECs 37-39. Opening of the BBB for < 1 h, typically using 25% mannitol
infused into a carotid artery, has been used to increase drug delivery to the brain 40.
This approach has not been reported with metal-based NPs. Focused ultrasound BBB
disruption has been used to open the BBB for a few hours to enhance
chemotherapeutic-magnetic NP brain delivery 41, 42. Direct uptake into the brain through
cranial nerves exposed to the environment provides another route, discussed below.
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VI.B. Sites lacking an intact blood-brain barrier
The rodent BBB begins to develop pre-natally. Intraperitoneal injection of 25 to 70 nm
anatase titania to mice on gestational days 3, 7, 10, and 14 resulted in titania in the
olfactory bulb and cerebral cortex and apoptosis in the olfactory bulb of 6 week old male
offspring. The NP presumably distributed into the brain before BBB development was
sufficient to prevent it 43. Given the insolubility of titania, the brain distribution and effects
were presumably due to intact NP.
There are sites lacking the BBB, which allow chemical communication between blood
and brain, including the periventricular organs, the chemoreceptor trigger zone, and
DRG. Forty nm latex microspheres were detected in vagal sensory ganglia a week after
their intra-tracheal instillation, suggesting uptake from the lung 44. This creates the
possibility of further distribution into the NS by retrograde (from the axon terminal
toward the cell body) axonal transport, as seen with polio and other retroviruses. No
reports were found assessing the relative ability of NPs to enter the brain at these
locations normally lacking an intact BBB compared to those that have a BBB.
VI.C. Nanoparticle uptake through the choroid plexuses
The structural basis of the brain’s BCSFB is the epithelial cell layer of the choroid
plexuses in the brain’s 4 ventricles. Reports of metal-based NP interaction with the
choroid plexus are limited to uptake of organic surface-coated iron oxides 45-47 .
Characterization of the size and other properties of NPs that enable their distribution
through the tight junctions of the choroid plexus epithelial cells has not been
determined. The steady state CSF/serum ratio appears to be the best available
parameter to characterize drug penetration into the CSF 48. The most relevant data, of
steady state protein in human lumbar CSF and blood serum, suggest the entry of a
compound into the CSF depends on the square root of its molecular mass 49.
Extrapolation from the protein results suggests CSF concentration would be ~0.5 and
0.25% of blood serum concentration for 4 and 10 nm NPs. No reports of distribution
into, or effects of metal-based NPs on, CSF were found other than a report showing
measureable cerium in CSF up to 90 days after a single i.v. administration of 30 nm
ceria 50.
VI.D. Direct uptake into the brain through cranial nerves exposed to the
environment
The only sites where the NS is directly exposed to the environment are nerve endings of
the olfactory nerves in the roof of the nasal cavity and the trigeminal nerve maxillary
division in the nasal cavity and roof of the mouth. Uptake from the nasal cavity into the
olfactory nerve, olfactory bulb, and across synapses to connecting neurons of the brain
was shown with 50 nm colloidal silver-coated gold 51. Translocation of ~35 nm 13Ccarbon particles along the olfactory pathway, and to a lesser extent into the cerebrum
and cerebellum 1 to 7 days later, was shown 52. Rats exposed by inhalation to ~30 nm
manganese agglomerates had up to a 3.5-fold increase of manganese in the olfactory
bulb, and lower (but significant) increases in 4 brain regions. Increases in gene and
protein expression indicative of inflammatory changes were most pronounced in the
olfactory bulb 53. Lectin-functionalized, polymer-coated, 95 nm QDs were taken up into
the brain following their nasal instillation 54. Whole-body inhalation exposure to spherical
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gold (primary particle size ~20 nm, airborne median size ~78 nm, 2 x 106 particles/cm3)
for 5 days significantly increased olfactory, septum, entorhinal cortex (the latter two
areas have direct neuronal connections from the olfactory bulb), and cerebellum (that
might have been bathed by gold in the CSF) gold 15 days later. However, given this
exposure route, the gold NPs might have entered systemic circulation from the nasal
cavity or lung and entered these brain regions through the BBB. There was no
verification that the gold in the brain was as gold NP, but due to its insolubility, this is
likely 55. On the other hand, whole-body inhalation exposure to spherical gold (4 to 5
nm, ~ 2.4 x 104, 2.4 x 105, or 1.8 x 106 particles/cm3) 6 hours/day, 5 days/week for 90
days did not increase olfactory bulb gold, and only increased brain gold in female rats
exposed to the highest concentration 56.
Toxic effects of intranasal NP administration have been reported. Intranasal application
of aqueous dispersions of 0.5 mg 80 nm rutile and 155 nm anatase titania every other
day for a month resulted in a time-dependent increase of titanium in the olfactory bulb,
cerebral cortex, hippocampus, and cerebellum; 25 to 30% cell loss in the hippocampal
CA1 stratum pyramidale region; increased pro-oxidant effects; and neuronal pathology
30 days later. Given the insolubility of titania NP, it was assumed the effects were due
to its translocation into the brain 57, 58. Ferric oxide NPs (21 nm) given by intranasal
instillation entered the axon of olfactory bulb neurons and produced significant prooxidant effects, dendrite degeneration, and membrane structure disruption in the
olfactory bulb, and an increase of hippocampal lysosomes 59. Similar repeated
instillation of 22 or 33 nm ferric oxide caused microglial cell activation and increased
BV2 microglial cell generation of reactive oxygen species (ROS) and generation of nitric
oxide but not cytokines, in vitro 60. Intra-nasal lipopolysaccharide-functionalized
cadmium selenide QDs activated microglia and increased nitric oxide generation, as
might be anticipated with the endotoxin 61. Intranasal instillation of gold rods produced a
biphasic microglial activation that was greater than the monophasic activation produced
by gold nano-urchins (gold NPs with small attached spines). Spheres produced little
effect 62. More details of these NPs are below (VIII.D.2 Physical-chemical factors that
affect biological responses, Shape). Every other day intranasal application of 33 to 380
nm silver for 2 weeks resulted in defects in spatial cognition (Morris water maze) and
long-term potentiation and increased hippocampal ROS. In the absence of brain silver
determination or demonstration of silver NP in the brain, the absorption route and
chemical species absorbed (NP vs. silver ion) are unknown 63.
A simulation model of 1 to 100 nm NP deposition (undefined composition and density)
to the rat’s nasal cavity and olfactory region using computational fluid dynamics to
assess particle size uptake dependence showed 95, 20, and 2% deposition in the nasal
cavity of the 1, 10, and 100 nm NPs. Deposition to the olfactory region was maximal for
3 to 4 nm NPs, mostly in the anterior nose 64. Direct uptake into human brain from the
nasal cavity might be less than in the rat due to the smaller percentage of the nasal
mucosa innervated by the olfactory nerve (5 vs. 50%) and because the human is not an
obligate nasal breather 65. However, results of a model suggest the concentration of a
20 nm particle may be greater in the human, than rat, olfactory bulb 65.
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Injection of colloidal radiolabeled gold under the mucous membrane of the rabbit’s nasal
roof resulted in the highest gold concentration in the CSF withdrawn most closely from
the site of injection. It was presumably taken up through the perivascular space around
the olfactory nerve, presenting another route of uptake from the nasal cavity into the
cranium 66.
VI. E. Direct introduction of nanoparticles into the brain
Metal-based NPs have been directly injected into the brain, bypassing the above
barriers. One approach is convection-enhanced delivery (CED) that employs a pump to
produce a pressure gradient to deliver an agent directly to the target (often tumor) site
via an implanted cannula 23. NPs containing metals as imaging agents have been
studied by CED. Iron oxide NPs, enabling MRI-image guidance, have been conjugated
to an epidermal growth factor antibody or albumin and methotrexate to treat
glioblastoma multiforme tumors 67, 68. CED of QDs to rat brain was not visualized by
clinical computed tomography (CT) or MRI in the live rat, but could be visualized in
excised fixed brain by high-resolution, small animal CT 69.
VII. THE PHARMACOKINETICS OF BRAIN NANOPARTICLE UPTAKE AND
DISTRIBUTION
The mechanisms of substance distribution into the brain include diffusion, carriermediated transport, and receptor-mediated processes (facilitated diffusion, active
transport, and endocytosis [cell absorption by engulfing particles and receptor mediated
uptake in small vesicles into a cell]) 70. A study with perfused 1 to 1.2 nm lanthanum did
not show flux through the BBB endothelial cell tight junctions of 1 to 14 day old rats 71.
Diffusion across the BBB favors small molecules (< 500 Da, ~1 nm) and lipophilic
substances. Endocytotic processes involve macropinocytosis, caveolae, clathrin-coated
pits, caveolae/clathrin-independent uptake, and phagocytosis. Caveolar uptake occurs
in non-fenestrated endothelial cells, involving an invagination of the cell membrane
surrounded by the protein caveolin on the cytoplasmic surface, receptor proteins, and
invagination into the cell. The caveolae-mediated uptake pit diameter is ~50 to 80 nm.
Uptake requires cellular stimulation. The clathrin-coated pit diameter is ~120 nm. An
example is transferrin binding to its receptor. Phagocytosis can engulf spherical
particles from ~0.2 to 3 µm into a vacuole. The BBB expresses many influx and efflux
transporters; most substrates are small molecules 72. NPs might hitchhike through the
BBB on peptide transporters such as transferrin - the molecular trojan horse approach.
No reports of transporter-mediated brain uptake of metal-based NPs were found. A
study using the in situ brain perfusion technique showed that 2 minutes after carotid
arterial perfusion of 5 nm ceria NP it was associated with the luminal wall of BMECs, but
had not entered those cells or brain parenchyma. Given more time, the NPs might cross
the BBB 39. Six hours after intraperitoneal injection captopril-conjugated QDs were
frequently seen in brain blood vessels but only occasionally in perivascular areas and
brain parenchyma of cerebral cortex, thalamus and olfactory bulb 73, consistent with the
very limited flux of metal-based NPs across the BBB (Figure 4).
Endocytotic processes are believed to be the major mechanism of NP cell uptake. They
are much slower than small molecule diffusion or transporter-mediated uptake,
demonstrated by clathrin-mediated uptake half-lives of 2.02, 1.88, and 2.52 hours for
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14, 50, and 74 nm transferrin-coated gold into SNB19 (brain tumor) cells 74. Metalbased NPs shown to be taken up by endocytosis include 6 to 20 nm silver NPs into
human glioblastoma (U251) cells 75 and ~77 nm gold urchins into N9 microglia 62.
Uptake of 70 nm silver NP into rat BMECs may have been mediated by transcytosis 38.
A role for clathrin was shown in the uptake of 120 nm L-DOPA-coated iron oxide into rat
brain capillary endothelial and choroidal plexus epithelial cells, and 40 and 200 nm
carboxylated polystyrene NPs into an astrocytoma cell line 46, 76.
Based on results of studies with gold nanospheres, nanorods and nano-urchins (see
VII.B. Subcellular nanoparticle localization) Hutter et al 62 suggested relatively thin
rods may have a more favorable morphology for cell internalization than the other two
forms. This may relate to the observation that nanorods enter cells perpendicularly to
their long axis 77. Results suggest endocytotic processes mediate NP uptake into
BMECs.
VII.A Nanoparticle factors that influence central nervous system (CNS) uptake
VII.A.1. Size
Smaller NPs enter the brain to a greater extent than larger ones. Figure 5 shows results
from several studies with various sizes of gold NPs, different surface functionalizations,
and using three different experimental methods. It appears that size, not charge,
influenced their permeation differences. Brain uptake results in Panels A through E do
not inform whether the NPs entered brain parenchyma or were confined to the vascular
compartment, the issue addressed in Figure 4. In a rat BMEC and astrocyte co-culture,
2.8% of 70 nm spherical silver NP vs. 0.1% of 12 µm silver particles crossed this in vitro
BBB model and 34 vs. 8% were associated with the BBB cells, respectively 38. Silver NP
flux was quantitatively much greater than in vivo reports of brain metal-based NP
uptake. This illustrates, along with Figure 5 Panel H (permeation through a co-culture
model of the BBB) compared to Figure 4 (lack of brain parenchymal uptake of PEGcoated gold NP), the greater leakiness of in vitro BBB models than the mammalian in
situ BBB.
After i.v. injection of 20 and 100 nm gold NPs only the smaller NPs were observed by
TEM in retinal neurons, endothelial cells, and peri-endothelial glial cells, suggesting
permeation of the blood-retinal barrier (BRB) 78. The BRB is comprised of endothelial
cells, pericytes, astrocytes, and tight junctions between epithelial cells. Bypassing the
BRB, intra-vitreal injection of various NPs has been shown effective to treat
angiogenesis-related blindness, retinal degeneration, and uveitis 79.
There was initially slightly more gold in the brain of mice after a single intraperitoneal
injection of 17 than 37 nm (surface charge - 46 to - 48 mV) gold NPs. Brain gold
increased over 21 days, possibly due to continued absorption or re-distribution from
other sites 80. Brain gold 24 hours after an intragastric administration of 1.4, 5, 18, and
80 nm radiolabeled gold was ~0.0003, 0.0001, 0.0015, and 0.0001% of the dose. The
differences could be due to absorption or BBB permeation 81. Intravenous administration
of mono-sulfonated triphenylphosphine gold NPs (1.4, 5, 18, and 80 nm, – 20 to – 23
mV; and 200 nm, – 41 mV) resulted in uptake that correlated with the volumetric specific
surface area for the 1.4 to 18 nm NPs, but not the larger ones 24 hours later (Figure 4)
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Evidence was not provided that the NPs entered brain parenchyma. This study
appears to be the only one assessing the dose metric that best describes NP brain
uptake, NP size.
There may be an optimal size for NP uptake by brain cells. A diameter of 55 nm
produces the fastest wrapping time for a membrane to enclose a particle, and therefore
greatest uptake by endocytosis 74. The optimal particle diameter to accelerate protein
wrapping of cylindrical and spherical particles, and their interaction with the lipid bilayer
of cell membranes, was found to be 30 and 60 nm, respectively 83. Smaller particles
might enter cells as agglomerates. A review of the physical-chemical effects of inorganic
NPs in relation to their size concluded that NPs with diameters of 30 nm or less have
characteristics that enhance their interfacial reactivity, giving them properties different
from their bulk components 84. This critical size for NPs, at which new properties
typically appear, is strongly related to the exponential increase in the number of atoms
localized at the surface 84. For 5 to 100 nm citrate-coated gold NPs, the maximal
association constant with albumin and histone was seen with the 60 nm particles; with
fibrinogen it was the 60 and 100 nm particles. NP association was considerably greater
with globulins and insulin and increased with NP size 85.
VII.A.2. Shape
No reports were found addressing the influence of NP shape on brain uptake in intact
organisms.
VII.A.3. Surface charge (in relation to luminal surface of brain endothelial cells)
The luminal to abluminal flux of neutral 60 nm maltodextrin NPs across a co-culture of
bovine BMECs and rat astrocytes was ~3-fold greater than anionic or cationic NPs.
When coated with a dipalmitoyl phosphatidyl choline and cholesterol lipid bilayer, flux of
the charged NPs increased 3- to 4-fold, whereas flux of the uncharged did not change
86. The binding of 60 nm maltodextrin NPs without, and with, a surface cationic ligand
(+25 mV), and cationic NPs with an anionic phospholipid (dipalmitoyl phosphatidyl
glycerol) in the core to give DPPG-NPs (+24 mV) to bovine BMECs was studied. The
cationic NP bound mainly around the paracellular area, the neutral NPs mainly on the
cell surface, and DPPG-NPs to both sites. There was no difference in flux of the neutral
and cationic NPs across a co-culture of bovine BMECs and mixed glial cells. Flux was
inhibited by filipin, showing dependence on the caveolae pathway 87. Rat brain uptake of
a 127 nm anionic (-60 mV) surfactant surface-coated emulsifying wax NP increased
above that seen with a 75 nm (-14 mV) less anionic or a 97 nm (+45 mV) cationic NP.
The order of disruption to BBB integrity was cationic > anionic > neutral NPs 88. Mouse
brain contained more positively-charged 362 nm 99mTechnectium-labeled etoposideincorporated tripalmitin than 391 nm negatively charged NPs after their i.v.
administration 89. However, there was no demonstration in the prior 2 studies that the
NPs crossed the BBB; they could have adsorbed on the luminal wall of, or been
sequestered in, the BMECs. The percent of the dose in rat brain of positively charged
(cysteamine-coated) 2.8 nm gold NPs was somewhat greater than negatively charged
(thioglycolic acid coated) ones 24 hours after their i.v. administration (Figure 4) 82. The
authors suggest alterations of the NP surface due to protein binding and exchange were
major mechanisms determining their accumulation in various organs and tissues. Gold
16

was seen in the brain after intragastric administration of a positively charged (NH3+) 2.8
nm gold NP (~0.00015% of the dose) but not after a negatively charged (COO-) 2.8 nm
one. The site causing the difference could be oral absorption or BBB permeation 81.
Conjugation of a 12 nm gold NP with an amphipathic peptide (CLPFFD) increased brain
distribution 4-fold compared to citrate-capped gold NP of the same size after their
intraperitoneal injection. The former had a smaller negative charge (-41 vs. -52 mV) and
was more hydrophobic. It did not alter BBB integrity and had no effect on cell viability 90.
No reports that clearly showed an influence of surface charge of metal-based NPs on
flux across the BBB were found.
VII.A.4. Surface coating (intended and opsonization)
The surface of an NP is never naked. Due to high energetic adhesive forces close to
the surface, NPs can agglomerate or adsorb to the next available biological or nonbiological surface 91. In vivo coating by the several thousand proteins in blood or lipids
(opsonization) is extremely important, because the NP surface is what cells see 92, 93.
NP coating can alter size, surface charge, and biological effects 94, 95. There is rapid
(within seconds) association with the most abundant proteins that shifts over time to
those with the highest affinity constant, i.e., protein sorption is often reversible. Some
proteins promote phagocyte clearance. Others, such as albumin and apolipoprotein,
prolong NP circulation time. The latter also interacts with BBB receptors to enhance
BBB transport. Cell membrane surfaces are negatively charged. Surface coating of
polymer NPs has been shown to influence their brain uptake 96. NP size, shape, and
surface area can influence interactions with proteins and cell components 97-99. The
binding of plasma proteins to silica, Aeroxide® P25 (Evonik Degussa ~80% anatase
20% rutile titania), and zinc oxide NPs was NP-dependent. For titania (the only NP
tested for the effect of shape), qualitatively more proteins bound to nanospheres than
nanorods or nanotubes 100. Multilayer protein binding has been observed between 5, 10,
20, 30, 60, 80, and 100 nm citrate-coated gold NPs and 5 plasma proteins. Association
was assessed using dynamic light scattering to estimate the apparent particle size of
the dispersions. Maximal association with albumin and histone was seen with the 60 nm
particles. With fibrinogen it was the 60 and 100 nm particles. It was considerably greater
with globulins and insulin and increased with NP size 85. The association altered protein
conformation; potentially contributing to toxicity. By comparing uncoated (hydroxyl
functionalized, that favors caveolar endocytosis), cationic polymer polyethyleneiminecoated (that favors adsorptive-mediated endocytosis), and prion protein-coated 500 nm
silica matrix magnetic core NPs in an in vitro BBB model, it was demonstrated that
charge and protein ligands affect their mode of internalization, transcytotic potential, and
intracellular localization 101. NP size and shape therefore influence the proteins that coat
them in vivo.
VII.B. Subcellular nanoparticle localization
When metal-based NPs have been localized in brain cells, they have usually been seen
in the cytoplasm, sometimes in vesicles, of microglia. However, there are reports of
intra-nuclear distribution. Two nm QDs were localized to the cytoplasm of N9 murine
microglial cells, whereas 5 nm QDs were in the nucleus 103. Twenty to 50 nm pegylated
QDs injected into mouse brain were in microglial lysosomes, but not microglial
mitochondria or nuclei, or neurons 104. Degussa P25 titania was seen in microglia
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vacuoles 18 hours after in vitro exposure 105. Silver NPs (6 to 20 nm) were visualized to
be uniformly distributed, including in the nucleus, of U251 human glioblastoma cells 75.
In contrast, peptide-coated 20 nm silver NPs, taken up by astrocytes in vitro, were seen
in cellular compartments, most likely lysosomes 106. Cetyl trimethylammonium bromide
(CTAB)-coated gold spheres and rods internalized into N9 microglia acidic lysosomal
compartments, whereas PEG-coated gold spheres and rods did not significantly
internalize. CTAB- and PEG-coated gold nano-urchins equally internalized, primarily
into cytosol. In contrast, CTAB- and PEG-coated gold nano-rods decorated the
dendrites and were internalized in the neurites and cell body of primary hippocampal
neurons whereas gold spheres and nano-urchins did not 62. After their intraperitoneal
injection 17 nm gold NPs were seen in the cytoplasm of hippocampal pyramidal cells,
surrounded by coated pit-like structures, suggesting endocytotic uptake, whereas 37 nm
gold NP did not enter neurons 80. NP size and surface coating therefore affect NP
subcellular distribution in NS cells.
VIII.THE PHARMACODYNAMICS OF NANOPARTICLES IN THE NERVOUS
SYSTEM
VIII.A. Blood-brain-barrier responses to nanoparticles
A cationic (97 nm, +45 mV) emulsifying wax NP increased brain cerebrovascular
volume to a greater extent than an anionic one (127 nm, -60 mV), which was greater
than a neutral NP (75 nm, -14 mV). These results suggest cationic NPs were most
disruptive to BBB integrity and that neutral and low-concentration anionic colloidal NPs
provide a better benefit-safety profile for drug delivery to the brain 88. A comparable
study with metal-based NPs was not found. Administration of ~50 nm silver, ~50 nm
copper, or ~60 nm aluminum NP intraperitoneally (50 mg/kg), intravenously (30 mg/kg),
carotid arterially (2.5 mg/kg), and intracerebroventricularly (20 µg in 10 µl) opened the
BBB in rats and mice, demonstrated by Evans blue-albumin brain entry and 1.2 nm
lanthanum extravasation. Brain edema, neuronal (distorted cell shape, chromatolysis
and degeneration, nuclear damage, eccentric nucleolus and sponginess) and glial
(reactive gliosis and perivascular gliosis, myelin loss, myelin vesiculation) changes were
seen. The effects were greater with the silver than the copper, which was greater than
the aluminum NP, and greater in the cerebellum than brainstem than hippocampus and
cortex, than thalamus and hypothalamus. The work did not show NP entry into
parenchyma 107, 108. The results demonstrate metal NPs can damage the BBB and
cause adverse brain changes. To test the hypothesis that stress can increase NPinduced brain pathology, 7 daily intraperitoneal injections of the ~50 nm silver and
copper NPs were compared to saline in rats whole-body exposed to 38°C for 4 h. The
silver NPs increased BBB disruption and brain edema and produced cognitive and
motor impairment more than copper NP injections 109.
Opening the BBB by injection of i.v. mannitol enabled brain entry of dimercaptosuccinic
acid-coated 4 nm iron oxide 110, consistent with the approach of disrupting the BBB with
hyper-osmotic mannitol to enhance brain uptake of therapeutic agents 90, 111. Following
large (50, 250, or 750 mg/kg) i.v. doses of a commercial ~30 nm ceria, increased brain
Evans blue and fluorescein were seen 1 and 20 hours later, but these increases were
seldom statistically significant, suggesting minimal disruption of BBB integrity 112, 113.
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An in vitro study with human BMECs exposed to alumina NPs showed dose- and timedependent reduction of viability, loss of mitochondrial potential, increased superoxide
production, and reduced tight junction protein (JAM-A, ZO-1 and ZO-2) expression 114.
I.v. administration of alumina NP (29 mg/kg) to rats produced claudin-5 and occludin
loss, suggesting they have the potential to compromise the BBB, perhaps via alterations
in mitochondrial function 114. Exposure of a rat BMEC and astrocyte co-culture to 25 nm
Aeroxide® titania, up to 20 µg/ml, concentration-dependently increased 14C-sucrose flux
(decreased BBB integrity) and decreased the vinblastine efflux/influx ratio (decreased pglycoprotein activity). These effects were much more sensitive to the NP than cell
viability, which was not affected up 200 µg/ml. The mRNA expression of structural (tight
junction), transport (caveolar), and detoxification (multi-drug resistant and breast cancer
related) proteins were depressed. Inflammatory gene expression increased. Titania
agglomerations were seen in BMEC and glial cells. The results suggest non-lethal
adverse effects on BBB function associated with intracellular, but not intra-nuclear,
titania NP 115. An amphipathic peptide-coated 12 nm gold NP showed higher brain gold
content (although maximally only 0.024% of the dose) than a less negatively charged
citrate-coated gold NP (maximally only 0.0048% of the dose), and no disruption of BBB
integrity 90. These studies suggest brain drug delivery in the absence of significant BBB
disruption is possible. However, an in vitro study with rat primary BMECs showed
greater pro-inflammatory responses with 25 and 40 nm than 80 nm silver NPs that
might lead to inflammation-mediated neurotoxicity 116. Forty and 60 nm copper NPs
(1.5 and 3 µg/ml) increased primary rat BMEC proliferation but 12.5 to 50 µg/ml
decreased it 117. Twenty-five µg copper NP/ml increased PGE2,TNFα, and IL-1β release
and 15 µg/ml increased BBB permeability; responses similar to those seen with silver
NPs 116, 117. The copper NP effects were size independent. It is not known if these
effects were due to the copper and silver NPs or if their ions contributed. Determining
the relative sensitivity to NPs of measures of disruption of BBB function, such as
viability, tight junction integrity, metabolic activity, and immune and inflammatory
processes seems warranted.
No reports were found of the assessment of NP effects on the BNB.
VIII.B. Animal responses to nanoparticles
A slight brain lesion characterized by hippocampal neuronal vacuoles indicating fatty
degeneration was seen after a single oral 5 g/kg dose of 80 and 155, but not 20, nm
titania (crystalline form not stated) to mice 118. Fourteen consecutive daily intraperitoneal
injections of 5, 10, 50, 100, or 150 mg/kg of 5 nm anatase titania to mice dosedependently increased brain titanium (more than a comparable dose of non-NP titania),
and increased many pro-oxidant endpoints, indicating oxidative stress 119. Daily oral
administration of this material for 60 days impaired spatial recognition memory after 10
or 50 mg/kg, which was associated with increased titanium, acetylcholine, glutamate,
and nitric oxide; decreased norepinephrine, dopamine, serotonin and their metabolites;
spongiocyte proliferation; changes in cations; and decreased ATPases in the brain 120.
Intraperitoneal injection of 21 nm Aeroxide® titania to mice previously treated with
lipopolysaccharide increased ROS and inflammatory cytokines and activated microglia,
indicating the potential for NPs to enhance inflammatory brain responses 121. Nose-only
exposure to 22 nm silver nanoparticles for 6 hour/day 5 days/week for 2 weeks resulted
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in gene product changes, including genes associated with motor neuron and
neurodegenerative diseases and immune cell function. The determination of silver or
silver NP in the brain was not reported 122.
VIII.C. Nervous system responses to nanoparticles not seen in the nervous
system
There are reports of NP effects on the NS in the absence of significant NP presence.
Potential mechanisms come from related work. Inhalation exposure to fine and ultrafine
air pollution particulates increased brain inflammatory markers, which might be
explained by either particulate uptake via the olfactory nerve or systemic cytokine
release and distribution into the brain 123. Another mechanism is potential activation of
peripheral autonomic or neuronal afferent pathways that result in modulation of CNS
activity 124. NP-induced DNA damage to fibroblasts in vitro was reported in the absence
of intracellular NP, mediated by NP interaction with the cell membrane 125.
VIII.D. Physical-chemical factors that affect biological responses
VIII.D.1. Size
Toxicity to N9 murine microglia was greater from 2.2 than 5.2 nm diameter cationic QDs
103. Twenty and 50 nm silver NPs were more toxic to C6 glioma cells than 100 nm NPs
126. To assess the physical-chemical properties of NPs that best predict toxicity, doseeffects of 5, 15, 40, and 80 nm citrate-capped spherical gold NPs were determined in
Drosophila melanogaster. Gold NPs decreased lifespan and fertility and increased
ROS, heat shock proteins 70 and 83, DNA fragmentation, and apoptosis. Lifespan
decreased as NP size decreased, when expressed as NP surface area. Comparing the
different sizes, concentration played a primary role in the toxicity; size and surface area
did not 127, 128.
VIII.D.2. Shape
Gold spheres (23 nm) coated with CTAB (42 mV) were more toxic to N9 glial cells than
PEG-coated spheres (-23 mV), CTAB- (47 mV) or PEG-coated (-23 mV) nano-rods, or
CTAB- (39 mV) or PEG-coated (-10 mV) nano-urchins 62. PEG-coated spheres and
nano-rods, but not PEG- or CTAB-coated nano-urchins, increased N9 granulocyte
macrophage colony-stimulating factor whereas PEG- and CTAB-coated nano-urchins
increased IL-1α but PEG-coated spheres and nano-rods did not 62. Protein-conjugated
silver sulfide ~65 nm spherical NPs inhibited C6 glial cell proliferation to a greater extent
than 40 by 200 nm rods, 50 by > 1000 nm wires, or bulk crystals 129. Coating and NP
shape can therefore affect glial response. Similarly, 43 nm gold spheres were more
toxic to a non-NS cell line (MDCK II) than 17 by 38 nm nano-rods 130.
VIII.D.3. Surface charge
Twelve nm magnetite surface coated with silane-NH2 or silane-COOH was more toxic to
C6 glioma, U251, and SHG-44 glioblastoma cells than when coated with meso-2,
3-dimercaptosuccinic acid or silane-short-chain PEG 126. Although ζ potentials were not
reported, the results suggest surface charge can affect NS cell response to NPs.
VIII.D.4. Surface coating
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Similar gold content of N9 microglia was seen after exposure to CTAB and PEG-coated
gold nano-urchins, which was greater than after exposure to CTAB or PEG-coated gold
spheres or rods 62. However, CTAB/trioctylphosphine oxide-coated QDs were toxic to
PC12 cells whereas mercaptopropionic acid QDs were not 131. Citrate-coated iron oxide
NPs were more toxic to C17.2 neural progenitor cells and PC12 cells and increased
ROS more than dextran-coated, carboxydextran-coated, or cationic magnetoliposomes
132, 133. Polydimethylamine-coated ~9 nm core iron oxide NPs reduced the viability of
primary cortical neurons from embryonic day 7 chicks to a much greater extent than
aminosilane- or dextran-coated particles. Toxicity was associated with removal of the
plasma membrane. Their ζ potential in water and Neurobasal® media (media that
support neuronal growth) was ~55 and -10 mV; 15 and 10 mV; and ~55 and -10 mV,
respectively, illustrating the effects of surface coating on surface charge and toxicity 134.
In contrast, surprisingly, alumina, silica, and tri-methoxy-caprylyl-silane coatings did not
modify the toxicity of anatase, rutile, or mixed crystalline form titania to DRG cells 135.
The surface coating of redox-active nanoscale zero-valent iron became more oxidized
over 11 months. This “aged” form generated less ROS in MV2 microglia. It reduced
viability of MV2 and N27 neuron cells less than the fresh (non-oxidized) NP form 102.
IX. NANOPARTICLE NERVOUS SYSTEM INTERACTIONS OUTSIDE OF THE BRAIN
IX.A. The blood-peripheral nerve barrier to nanoparticle uptake into the peripheral
nervous system (PNS)
Similar to the CNS, neurons in the PNS are protected by the tight junctions and
transporters of the endoneurial endothelial cells and pericytes, but no astrocyte foot
processes, creating the BNB. Little has been reported on metal-based interactions with
the PNS. Nerve growth factor-conjugated QDs were shown to enter DRG neurons and
be retrograde axonally transported 136. Non-functionalized 2 to 3 nm cadmium telluride
QDs were taken up by DRG cells and transported to the cell body by retrograde axonal
transport 137. Silicon dioxide (< 12 nm) NPs were taken up by Schwann, but not DRG,
cells 138.
IX.B. Nanoparticle effects on the spinal cord and peripheral nervous system
Non-functionalized 2 to 3 nm cadmium telluride QDs taken up by DRG cells produced
greater toxicity than their constituent elements and were more toxic to DRG than PC12
cells (as shown by intracellular glutathione depletion and inhibition of neurite outgrowth)
137. Twenty nm lead oxide particles repeatedly given to rats by intra-tracheal instillation
decreased rearing and increased ambulation, increased high-frequency
electrocorticogram activity, increased somatosensory cortical evoked potential latency,
and decreased conduction velocity in the tail nerve 139. These results could be due to
CNS and/or PNS effects and NP translocation from lung, or to dissolution of the lead
oxide. Apoptosis induced by titania (anatase, rutile and mixtures; 11 to 31 nm) in chick
embryo DRG cells was not abrogated by the several inorganic and organic surface
coatings tested 135; cell uptake was evidently not examined. Anatase titania NPs dosedependently decreased DRG survival to a greater extent than Schwann cells, IC50 ~5
and 25 µg/ml, respectively 140. Silica (< 12 nm) NP taken up by Schwann cells reduced
their survival (IC50 ~150 µM). DRG cells, which did not appear to take up this NP, were
less affected 138. Repeated intraperitoneal injection of 50 to 60 nm aluminum, copper,
and silver NPs exacerbated trauma-induced spinal cord pathology, associated with
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breakdown of the PNS barrier to serum proteins 141. When applied to the spinal cord 5
minutes after injury, titanium-containing nanowires (with diameters of 50 to 60 nm,
surface modified) improved motor function and decreased blood-spinal cord barrier
disruption and spinal cord edema 142. Chitosan-gold NPs enhanced rat sciatic nerve
axon repair after injury 143. Application of 3 to 5 nm ceria (10 nM) to cultures of spinal
cord cells isolated from 3 to 4 month old rats increased the live-to-dead-cell ratio 15 and
30 days later, attributed to an anti-oxidant effect of the nanoceria to scavenge free
radicals 144. As with CNS cells, NPs can enter PNS cells to produce effects that are NPand cell-type dependent.
X. IN VITRO STUDIES WITH BRAIN-DERIVED CELLS
There are well recognized advantages and shortcomings of in vitro testing. The
complexity of the human NS cannot be adequately modeled in cell culture experiments
145. As noted above, BBB cell culture models do not have the same degree of
impermeability as the in situ BBB. Due to the formidable barrier properties of the BBB,
in vitro studies of NP uptake and effects are informative, but not necessarily
representative of what would be expected in the whole organism. Without
understanding the extent of NP penetration into the NS, where the NP could be taken
up by neural and glial cells, a complete understanding of the potential benefits and risks
is lacking. NP uptake has been shown in NS cells, including astrocytes 146, 147, microglial
cells 105, 148, and neurons 148. Greater uptake of peptide-coated 20 and 40 nm silver NPs
was seen with the astrocytes than neurons of a mixed primary cortical neural cell culture
consisting mainly of neurons and astrocytes, with some oligodendrocytes 106,
demonstrating cell type-dependent response.
Many NP effects on NS cells in culture have been reported, illustrating their potential to
produce NS cell toxicity. Examples are cadmium tellurium and cadmium selenium QDs
on hypothalamic glial, hippocampal neural, N9 microglial, IMR-32 and SH-SY5Y human
neuroblastoma, and PC12 cells 103, 149-152; anatase titania, zinc oxide, and magnesium
oxide NPs on human glioblastoma astrocytoma U87 cells 153; and a commercial
magnetic NP on microglia 154. Interpretation of NP uptake by NS cells in vitro and effects
of NP exposure results should be couched in terms of the ability of these NPs to
distribute across the BBB, BNB, and/or BCSFB into the NS of the intact organism.
Mesenchymal stem cells can undergo neuron-like differentiation. SPIONs were used as
MRI contrast agents and to label cells. It was shown possible to label human amniotic
membrane-derived mesenchymal stem cells without producing significant toxicity 155.
XI. VALIDATION THAT IN VITRO APPROACHES PREDICT IN VIVO EFFECTS
No reports were found that directly addressed validation of in vitro endpoints with in vivo
data using NS cells. There are a number of studies that used both in vivo and in vitro
models. There was generally decent agreement, suggesting in vitro models may predict
in vivo responses.
XII.NANOPARTICLE INTERACTION WITH INFRA-MAMMALIAN ANIMAL SPECIES
(ZEBRAFISH, C. ELEGANS, AND DROSOPHILA)
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There may be value in studying small intact organisms that have the full complement of
organ systems, require less cost and test material, and have short time spans. They
enable developmental, life-span, aging, and multi-generational studies in much less
time than traditional mammalian models. The zebrafish, which has 80% homology to the
human genome, has been utilized to study NP developmental effects. Exposure to 5 to
20 nm bovine serum albumin-capped silver resulted in a few scattered primary particles
in the zebrafish embryo brain 156. Microinjection of anatase titania NP into the otic
vesicle produced significant effects on gene regulation 157. Titanium was found in the
brain after titania NP exposure 158. Anatase titania NP was more toxic to brain
biochemical endpoints than its bulk material counterpart 159. Exposure from 6 to 24 or
48 hours post-fertilization to N,N,N-trimethylammoniumethanethiol (TMAT)-,
2-mercaptoethanesulfonic acid (MES)-, or 2-(2-(2-mercaptoethoxy)ethoxy)ethanol
(MEEE)-functionalized 1.5 nm gold NPs resulted in similar uptake, but greater mortality
and genetic effects from TMAT than MES than MEEE, suggesting surface
functionalization influenced the differential responses 160. Nerve impulse transmission
gene expression was enhanced. Exposure to titania NP from fertilization to free
swimming stage produced adverse behavioral deficits that were more sensitive than
hatchability and survival effects 161. Initial results with zebrafish suggest it predicts
effects expected in mammalian organisms.
The adult C. elegans hermaphrodite has 302 neurons that belong to two distinct and
independent NSs: a large somatic (282 neurons) and a small pharyngeal NS (20
neurons). It has 959 somatic cells. Its genome has been sequenced. Five nM ceria (8.5
nm) in the food source increased ROS accumulation and oxidative damage and
decreased lifespan. No NS endpoints were reported 162. Zinc NP and zinc ion produced
equipotent effects on movement 163. More work with this organism will be needed to
determine how well it predicts higher organism NS responses.
A study of drosophila response to citrate-capped spherical gold NPs is summarized in
VIII.D.1 Size
Sidebar 1: Pharmacokinetics of gold nanoparticle nervous system entry, influencing
factors, and extent of entry
To illustrate the current understanding of metal-based NP interaction with the NS, gold
was selected because it has been used in many studies of NP distribution into the NS
and resultant effects. Its size, shape, purity, and surface functionalization and charge
can be easily manipulated during synthesis; it can be quantified by very sensitive
analytical methods and visualized by TEM; and it has very low background
concentrations. Gold NPs have been surface coated with many agents, including citrate
to increase aqueous stability (e.g., the NIST standard reference materials); an
amphipathic peptide derived from β-amyloid 90; transferrin and PEG to target cancer
cells 164; radioactive iodine and tripeptide-PEG as probes for targeting cancer cells and
imaging tumor sites 165; with epidermal growth factor to enhance brain uptake 166; gellan
gum as a capping and reducing agent and further conjugated with sophorolipids 167; and
encapsulated in a ternary mixture of dioleoylphosphatidylcholine, sphingomyelin, and
cholesterol to increase resistance to aggregation 168. Gold NPs are also insoluble, so
levels can be confidentially attributed to the NP. As seen with other NPs, small (4 and
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13 nm) gold circulated in blood longer than a larger (100 nm) NP and little was excreted
in bile or urine 18 , 50. The mononuclear phagocyte system sequesters most NPs from
the blood, including gold NPs 18, 82, 90, 169. Elevated brain gold was seen following i.v.,
inhalation, intraperitoneal, and intragastric gold NP exposure. Brain gold concentration
inversely correlated with NP size (Figure 4) 82, 170, 171. In the absence of PEG coating,
brain gold was usually ≤ 0.01% of an i.v. dose; PEG coating increased brain uptake, but
did not result in preferential gold NP distribution to the brain (Figure 4) 171, 172. Even less
gold entered the brain after oral administration due to very low oral NP bioavailability 30,
81. Positively-charged gold NPs resulted in higher brain gold than negatively charged
ones. Clathrin-mediated endocytotic processes mediate gold NP cell uptake, with
uptake half-lives of ~2 hour 74. Intracellular gold NPs have been seen in the cytosol and
lysosomal compartments of neural and glial cells 62. Repeated intraperitoneal injection
of 12 nm citrate-coated gold resulted in a dose-dependent increase of brain gold 1 day
later 169, consistent with the bioaccumulation of insoluble NPs that are too large to be
filtered by the kidney. Bioaccumulation and prolonged retention has been shown with
gold 18 and other insoluble NPs, including ceria 50, Thorotrast® (a colloidal solution of ≥
45 nm aggregates of thorium dioxide 173), 70% anatase 30% rutile titania 174, and QDs
175.
Sidebar 2: Gold nanoparticle nervous system pharmacodynamics
Gold NPs are being investigated for imaging, tracking and labeling (including CT,
Raman spectroscopy and TEM); as drug and gene delivery carriers; as
photothermal/photodynamic therapy agents; sensors; electronic conductors; and
catalysts 166, 176-179. Although insoluble, “colloidal metallic gold is not bio-inert” 180.
Intraperitoneal injection of 8 mg/kg/week of 8 to 37 nm naked gold NPs to mice was
lethal within 1 month, whereas 3, 5, 50, and 100 nm NPs were not. Toxicity was seen in
the liver and spleen, organs that accumulate NPs. The brain was not affected. These
results are consistent with the size dependent effects of NPs and their inability to readily
enter the brain181. Intranasal gold NP was shown to activate microglia in a NP-shapedependent manner. CTAB-coated gold spheres were more toxic than similarly coated
nano-rods or nano-urchins, although showing less cell uptake 62. However, CTAB is
toxic and these results may reflect the surfactant equilibrium. Sub-retinal injection of
goat IgG-adsorbed gold NPs produced outer retinal degeneration 1 week later in the
rabbit 182. Citrate-capped spherical gold NPs (~50 nm) injected into the brain of the false
dead-head roach (Blaberus discoidalis) were seen in the brain and nerve cord,
demonstrating neuronal transport. Decreased locomotion was seen 2 to 6 weeks later.
The NPs were protein encapsulated, as is seen with NPs in vivo 183. These results
illustrate the uptake, effects, and opsonization of metal-based NPs. Although it has
been suggested gold nanorods might produce an asbestos-like mesothelioma similar to
that produced by high-aspect-ratio carbon nanotubes, there are no reports of studies
that assessed this. A study of 3 to 60 nm gold NPs in primary rat brain microvessel
endothelial cells showed only moderately decreased cell viability with the small gold
NPs at concentrations ≥ 7.8 μg/cm2 cell surface area and no change in basal levels of
various pro-inflammatory mediators, in cell morphology, or in BBB integrity 184,
demonstrating an exposure level producing little effect. There appears to be only one
dose-response assessment of gold NP toxicity to the NS in vivo that defines a lowest
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observable effect level (LOEL) and no observable (observed) effect level (NOEL). It is
reviewed in a risk assessment context in 2.
XIII. CONCLUSIONS AND RESEARCH NEEDS
Knowledge of colloid chemistry can significantly advance the development of surfacemodified NPs and our understanding of NP opsonization in biological milieu. Much work
has been done with cells in culture as proof of the concept that novel NPs interact with
NS cells. Less work has been done testing those materials in vivo. Given the formidable
barriers to NS entry provided by the BBB, BCSFB, and BNB, there is great need to
advance the study of these materials in the intact whole animal.
In vitro results with metal-based NPs suggest cause for concern, but in vivo results
show very low NP brain entry. Given the very low distribution of NPs into the NS, much
work has been done using exposure concentrations and doses that exceed expected
acute exposure, although they may model achievable levels after repeated exposure of
biologically insoluble NPs. To advance the risk assessment process, lower exposures
and multiple doses also need to be studied to determine the NOEL/LOEL of the
hazards. Future in vitro NS studies should be designed with exposure conditions
relevant to NP concentrations that might be achieved in vivo. The status of the literature
on interactions of metal-based NPs with the NS is summed up well by 178, who referred
to gold NPs: “Because many teams began their projects independently, there is a great
scatter in experimental design, including particle size and shape, functionalization
methods, animal types, particle administration doses and methods and so on.
Correspondingly, there is a large scatter of data and conclusions on the levels and
kinetics of biodistribution and on toxicity estimates”. There is a need for work that
employs one or a few model, well-characterized, NPs. Gold would be a good candidate.
It should include single and repeated exposure (inhalation and i.v.) to multiple doses
and resultant NS biodistribution and effects (perhaps compared to other sites). Parallel
work should be conducted in vitro with comparable concentrations as those seen in the
NS to determine if there are similar responses, as well as similar persistence,
accumulation, and effects from repeated exposure. Because NPs are colloids, it is
particularly important that their surface chemistry in the various milieux be understood
and related to their behavior and effects. The work should maintain the subjects long
enough to assess NP persistence, possible resolution (adaptation or compensation) of
shorter-term effects, and any delayed effects. A concern is the potential for toxicity
associated with NP accumulation from repeated exposure, which would be predicted
with NPs that are too large to be cleared by the kidney, insoluble and therefore retained
for a prolonged time, and have demonstrated toxicity after single large-dose exposure,
e.g., 50, 185. Other topics that have been minimally addressed (if at all) include 1)
adverse effects of metal-based NPs on the choroid plexuses, 2) metal-based NP
distribution to the spinal cord or PNS, and 3) the relative sensitivity to NPs of measures
of disrupted BBB function, such as viability, tight junction integrity, metabolic activity,
and immune and inflammatory processes. These warrant study.
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Figure Captions:
Figure 1. Interfacial double layers near colloidal particles. Collodial particle = black
sphere. Positive ions (pink). Negative ions (blue).
Figure 2. Results of SciFinder® searches of A) all publications of NPs and those using
in vitro and in vivo study platforms, B) metal-based NP nervous system publications by
metal, and C) metal-based NP nervous system studies by research platform.
Figure 3. Global NP patent activity for all NPs and selected metal-based NPs.
Figure 4. NP distribution into the brain, expressed as a percentage of the dose and time
after NP administration. Red = Unable to find the NP in the brain or reported that it was
not in the brain. Black = Brain NP can be attributed to its presence in the brain’s
vascular compartment and the report provides no evidence of NP distribution into brain
parenchyma. Blue = Brain NP is too high to be attributed to its presence in the brain’s
vascular compartment but the report provides no evidence of NP distribution into brain
parenchyma, so the NP could have been associated with BBB cells but did not enter
brain parenchyma. Green = The report provides evidence of NP distribution into brain
parenchyma.
Figure 5. Influence of NP size on brain uptake. Panels A through E: The percentage of
gold NP dose in rat or mouse brain. Panels F and G: The percentage of the gold NP
dose taken up into rat primary BMECs per mg protein. Panel H: The percentage of the
gold NP dose that permeated through rat BMECs. Asterisks indicate NP sizes that were
* not detectible, ** below control, or *** reported as 0. The ζ potential of the PEG-coated
gold NPs was ~- 2 to - 11 mV. The dendrimers were an acetamide PAMAM. Uptake in
rat BMECs was conducted with primary cells. Rat brain permeation was through an
endothelial and astrocyte cell co-culture. From: Panel A 170 , B 186, C 171, D and E ones
187, F and G 184, and H 188.
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Figure 5. Dimple is upper casing first letter of appropriate words in titles above panels and X and Y axes
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Table 1. The pH of some body fluids, organs and tumors.
Site

pH

Reference

Blood

7.35

Lung bronchioalveolar fluid

6.25

189

Oral cavity

7.4

190

Stomach

1-2, up to 4 during proton pump inhibitor
therapy

191

Jejunum

6.05

192

Duodenum

6.25

192

Small intestine

7.4

193

Ileum

7.5

194

Cecum

6

194

Large bowel

5.7

194

Brain extracellular fluid

7.3

195

Lysosome

4.5

196

Endosome

6

196

Tumor (extracellular)

6.5 to 6.9

197
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